Lipid management in patients with chronic kidney disease (Q58561315)

Author Correction: Lipid management in patients with chronic kidney disease

inferred from title

corrigendum / erratum

0 references

13

Raymond Vanholder

0 references

Patrick Rossignol

6

Patrick Rossignol

0 references

Marianne C. Verhaar

11

Marianne C Verhaar

0 references

Jolanta Małyszko

10

Jolanta Malyszko

0 references

Jose M Valdivielso

Jose M. Valdivielso

9

0 references

Alberto Ortiz

Alberto Ortiz

15

0 references

Marianne C. Verhaar

11

Marianne C. Verhaar

0 references

author name string

Charles J Ferro

1

0 references

Patrick B Mark

2

0 references

Mehmet Kanbay

3

0 references

Pantelis Sarafidis

4

0 references

Gunnar H Heine

5

0 references

Ziad A Massy

7

0 references

Francesca Mallamaci

8

0 references

Jose M Valdivielso

9

0 references

Robert Ekart

12

0 references

Gerard London

14

0 references

Alberto Ortiz

15

0 references

Carmine Zoccali

16

0 references

Charles J. Ferro

1

0 references

Patrick B. Mark

2

0 references

Gunnar H. Heine

5

0 references

Patrick Rossignol

6

0 references

Ziad A. Massy

7

0 references

Raymond Vanholder

Nature Reviews Nephrology

13

0 references

language of work or name

English

0 references

publication date

25 October 2018

0 references

published in

0 references

volume

14

0 references

page(s)

727-749

0 references

issue

12

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/s41581-018-0072-9

0 references

cites work

Summary of Recommendation Statements

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the E

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

2016 European Guidelines on cardiovascular disease prevention in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipoprotein(a) in nephrological patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Chronic kidney disease as cause of cardiovascular morbidity and mortality

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cardiovascular and noncardiovascular mortality among patients starting dialysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

UK Renal Registry 17th Annual Report: Chapter 5 Survival and Cause of Death in UK Adult Patients on Renal Replacement Therapy in 2013: National and Centre-specific Analyses

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Update on the long-term complications of renal transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cardiovascular risk factors following renal transplant

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Reducing the costs of chronic kidney disease while delivering quality health care: a call to action

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Prevention of cardiovascular disease in adult recipients of kidney transplants

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cardiovascular risk assessment in kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Reduction in cardiovascular death after kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Dyslipidemia in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Dyslipidemia in renal disease: causes, consequences and treatment

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

New insights into lipid metabolism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cholesterol Metabolism in CKD

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

High-Density Lipoprotein in Chronic Kidney Diseases-The Devil Is in the Detail.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipid and lipoprotein metabolism in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Dyslipidemia associated with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

New perspectives on CKD-induced dyslipidemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipoprotein metabolism and lipid management in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipoprotein heterogeneity: diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The ABC transporters in lipid flux and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Uraemic plasma decreases the expression of ABCA1, ABCG1 and cell-cycle genes in human coronary arterial endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Serum apolipoprotein profile of patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Oxidized lipids as mediators of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Dysfunctional high-density lipoprotein in patients on chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Kidney Function as a Determinant of HDL and Triglyceride Concentrations in the Australian Population

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipoprotein lipase: structure, function, regulation, and role in disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Acquired VLDL receptor deficiency in experimental nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Down-regulation of VLDL receptor expression in chronic experimental renal failure

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Triglycerides and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: the Multi-Ethnic Study of Atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Current therapies for lowering lipoprotein (a)

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Genetic associations with valvular calcification and aortic stenosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Oxidative stress is progressively enhanced with advancing stages of CKD

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Oxysterol profiles of normal human arteries, fatty streaks and advanced lesions

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Characterization and comparison of the mode of cell death, apoptosis versus necrosis, induced by 7beta-hydroxycholesterol and 7-ketocholesterol in the cells of the vascular wall

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Role of reactive aldehyde in cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Oxidized LDL: diversity, patterns of recognition, and pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Oxidative Stress Biomarkers and Left Ventricular Hypertrophy in Children with Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

LDL cholesterol in CKD--to treat or not to treat?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

HDL abnormalities in nephrotic syndrome and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Post-transplant dyslipidemia: Mechanisms, diagnosis and management

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cyclosporine, low-density lipoprotein, and cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosp

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Premature cardiovascular disease in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The China Kidney Disease Network (CK-NET): "Big Data-Big Dreams".

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

UK Renal Registry 19th Annual Report: Chapter 5 Survival and Causes of Death in UK Adult Patients on Renal Replacement Therapy in 2015: National and Centre-specific Analyses.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Arterial stiffness in chronic kidney disease: causes and consequences

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Arterial disease in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Diffuse intermyocardiocytic fibrosis in uraemic patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Association between serum lipids and survival in hemodialysis patients and impact of race

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of extended-release niacin with laropiprant in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Association of serum lipids with outcomes in Hispanic hemodialysis patients of the West versus East Coasts of the United States

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Triglycerides and the Risk of Coronary Heart Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Causes of dysregulation of lipid metabolism in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Chronic Kidney Disease in Non-Diabetic Older Adults: Associated Roles of the Metabolic Syndrome, Inflammation, and Insulin Resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Interpretation of the evidence for the efficacy and safety of statin therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of lowering LDL cholesterol on progression of kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Statins evidence: when answers also raise questions

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Association between LDL-C and risk of myocardial infarction in CKD

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The role of lipoprotein (a) in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

HMG CoA reductase inhibitors (statins) for dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Meta-analysis of lipid-lowering therapy in maintenance dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Inflammation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Elevated plasma F2-isoprostanes in patients on long-term hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Update on inflammation in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Inflammation and Progression of CKD: The CRIC Study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Pleiotropic Effects of Statins on the Cardiovascular System

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Fibrate-induced increase in blood urea and creatinine

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Fibrate therapy and renal function

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Safety considerations with gastrointestinally active lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology T

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Managing dyslipidemia in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Review of the effects of omega-3 supplementation in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Overview of prescription omega-3 fatty acid products for hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Why do omega-3 fatty acids lower serum triglycerides?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

New Era of Lipid-Lowering Drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Proprotein convertase subtilisin/kexin type 9 inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

1 reference

7 January 2021

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Molecular biology of PCSK9: its role in LDL metabolism

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II t

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Trials and Tribulations of CETP Inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Safety of anacetrapib in patients with or at high risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, [...]

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

No small task: therapeutic targeting of Lp(a) for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Multiple functions of microsomal triglyceride transfer protein

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Development of Antisense Drugs for Dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

New approaches to target microsomal triglyceride transfer protein

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

New Therapeutic Approaches for Familial Hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinica

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Apolipoprotein A-I Infusion Therapies for Coronary Disease: Two Outs in the Ninth Inning and Swinging for the Fences

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

ATP-citrate lyase: a mini-review.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr-/- Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR+/- and LDLR-/- ) Yucatan Miniature Pigs.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled,

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Comparative Evaluation of Gemcabene and PPAR Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Atenolol in hypertension: is it a wise choice?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Revascularization versus medical therapy for renal-artery stenosis

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

How much will Herceptin really cost?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Clinical trials in children

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Women's involvement in clinical trials: historical perspective and future implications

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The effects of the Danish saturated fat tax on food and nutrient intake and modelled health outcomes: an econometric and comparative risk assessment evaluation.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Individualized guidelines: the potential for increasing quality and reducing costs

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Clinical guidelines, the politics of value, and the practice of medicine: physicians at the crossroads

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Monitoring cholesterol levels: measurement error or true change?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Lipid re-screening: what is the best measure and interval?

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Kidney function and long-term medication adherence after myocardial infarction in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Protein Nutrition and Malnutrition in CKD and ESRD.

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Statins in the management of dyslipidemia associated with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Adverse effects of statins - mechanisms and consequences

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021

Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41581-018-0072-9

7 January 2021